ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2158

Baseline Folate Related Biomarkers in Serum and erythrocytes Are Not Associated with Methotrexate Response and Adverse Events in Rheumatoid Arthritis

Maurits C.F.J. De Rotte1, Saskia M.F. Pluijm2, Maja Bulatovic3, Johanna M.W. Hazes4 and Robert De Jonge1, 1Clinical Chemistry, Erasmus Medical Center, Rotterdam, Netherlands, 2Public Health, Erasmus Medical center, Rotterdam, Netherlands, 3Department of Paediatric Immunology, University Medical Centre Utrecht, Netherlands, 4Rheumatology, Erasmus MC, Rotterdam, Netherlands

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Adverse events, longitudinal studies, methotrexate (MTX), outcome measures and vitamins

  • Tweet
  • Email
  • Print
Session Information

Title: Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy

Session Type: Abstract Submissions (ACR)

Background/Purpose: Methotrexate (MTX) is the most commonly used drug in rheumatoid arthritis (RA). 30% of patients fail to respond to the drug or suffer from adverse events. Therefore, there is a need to identify determinants of MTX response and adverse events in RA. MTX is an antagonist for folate and interferes with folate homeostasis. We investigated whether folate-related biomarkers, including homocysteine (HCy), vitamin B6, B12 and folate, measured at baseline were associated with MTX response and adverse events over nine months of treatment.

Methods: The study included patients from two longitudinal cohorts who were diagnosed with RA according to the 2010 ACR criteria and were treated with MTX therapy: 285 patients from the treatment in Rotterdam Early Arthritis Cohort (tREACH) (1) and 99 from the Methotrexate in Rotterdam (MTX-R) study. Serum concentrations of HCy, B6, B12 and folate, and folate in erythrocytes were determined at baseline (t0). MTX response was assessed with the disease activity score (DAS)-28 at 0,3,6 and 9 months after MTX start and EULAR response criteria at 3,6 and 9 months. Adverse events were defined as gastro-intestinal intolerance and overall complaints at 3,6 and 9 months. Using DAS 28 as outcome measure, analysis of covariance (ANCOVA), adjusted for age, gender, DAS28 at baseline, MTX dose, MTX route of administration, other DMARDs, NSAIDs, steroids and study cohort, was used. EULAR and adverse events were analyzed with logistic regression. Biomarkers were analyzed as continuous variables, quintiles and tertiles.

Results: Concentrations at baseline (mean/SD) were: homocysteine: 12.9 μmol/l (5.9), B6: 93 nmol/l (97), B12: 322 pmol/l (131), folate in serum: 23 nmol/l (35) and folate in erythrocytes: 1007 nmol/l (450). DAS28 was 4.76 (1.26) at baseline and 3.08 (1.20), 2.91 (1.22), 2.68 (1.16) at 3,6 and 9 months. 52%,26% and 24% had gastro-intestinal complaints at 3, 6 and 9 months, respectively. 46%, 49% and 47% of the patients reported one or more adverse events at 3 6 and 9 months of follow-up.

None of the biomarkers (defined as continuous measure) were associated with DAS28 at all 3 time-points (table). For HCy we only found a positive association at 6 months (standardized-ß = 0.18, p = 0.001), whereas folate in erythrocytes was only associated negatively with DAS28 at 3 months (st-ß = -0.14, p = 0.017). Analyses with biomarkers divided into quintiles or tertiles showed similar results. In addition, no associations were found between any of the baseline biomarkers and EULAR response criteria or adverse events.

Conclusion: In this first longitudinal study, folate-related biomarkers were unrelated to MTX treatment outcome in RA.

Funds: RDJ: Dutch Arthritis Association (nr. 06-02-402, 09-01-402).

Reference: 1. De Jong PH, et al. Ann Rheum Dis. 2012 Jun 7.

 


Disclosure:

M. C. F. J. De Rotte,
None;

S. M. F. Pluijm,
None;

M. Bulatovic,
None;

J. M. W. Hazes,
None;

R. De Jonge,

Dutch Arthritis Association,

2.

  • Tweet
  • Email
  • Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/baseline-folate-related-biomarkers-in-serum-and-erythrocytes-are-not-associated-with-methotrexate-response-and-adverse-events-in-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology